Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

1.030 +0.060 (+6.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Invivyd
Via GlobeNewswire
3 Groundbreaking Biotech Stocks to Invest in Now
These are several biotech companies for investors seeking unique opportunities for great returns within the industry. 
Via InvestorPlace
Apple To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
The biggest pre-market stock movers for Wednesday are ready to go as we break down all of the latest news moving shares today! 
Via InvestorPlace
Recap: Invivyd Q3 Earnings
 
Via Benzinga
Invivyd's Earnings: A Preview
 
Via Benzinga
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
From Invivyd
Via GlobeNewswire
Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?
The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment. 
Via The Motley Fool
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company... 
Via Benzinga
Topics Stocks
Nasdaq Gains 100 Points; Biomerica Shares Spike Higher
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07.... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Crude Oil Rises 3%; US Housing Market Index Increases In December
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Monday. The Dow traded up 0.14% to 37,356.29 while the NASDAQ rose 0.25% to 14,851.19. The S&P 500... 
Via Benzinga
Topics Stocks
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
Why Is COVID-19 Antibody Focused Invivyd Stock Trading Over 150% Higher Today?
Invivyd Inc (NASDAQ: IVVD) shares are trading higher after the company released initial results from the ongoing CANOPY Phase 3 pivotal clinical trial of VYD222, a broadly neutralizing, half-life... 
Via Benzinga
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
From Invivyd
Via GlobeNewswire
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 
From Invivyd
Via GlobeNewswire
7 Biotech Stocks to Sell in September Before They Crash & Burn
These are just a few of the top biotech stocks to sell today - especially with each of the firms dealing with legitimate issues. 
Via InvestorPlace
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Invivyd Appoints William Duke as Chief Financial Officer
From Invivyd
Via GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Dentsply, and Invivyd on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
From Invivyd
Via GlobeNewswire
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
From Kahn Swick & Foti, LLC
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.